**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 70670

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Sodium nitroprusside injection immediately before balloon inflation during percutaneous coronary intervention**

Yu Y *et al*. Sodium nitroprusside injection during PCI

Yan Yu, Bao-Ping Yang

**Yan Yu, Bao-Ping Yang,** Department of Cardiovascular Medicine, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, Gansu Province, China

**Author contributions:** Yu Y and Yang BP contributed to the writing and revising of the manuscript.

**Supported by** 2020 Gansu Planning Projects on Science and Technology, No. 20JR10RA352.

**Corresponding author: Bao-Ping Yang, BSc, Associate Chief Physician,** Department of Cardiovascular Medicine, Gansu Provincial Hospital of Traditional Chinese Medicine, No. 418 Guazhou Road, Qilihe District, Lanzhou 730050, Gansu Province, China. ybp1788@163.com

**Received:** August 10, 2021

**Revised:** October 7, 2021

**Accepted:** November 3, 2021

**Published online:** December 26, 2021

**Abstract**

BACKGROUND

No reflow or slow flow frequently occurs during percutaneous coronary intervention (PCI) and it is associated with adverse outcomes. Strategies should be undertaken to prevent its occurrence.

AIM

To observe whether conventional target intracoronary administration of sodium nitroprusside immediately before balloon inflation can reduce the incidence of no reflow and slow flow, which are defined as thrombolysis in myocardial infarction flow grade ≤ II during PCI.

METHODS

A retrospective study was conducted in 740 patients with coronary artery disease admitted to Gansu Provincial Hospital of Traditional Chinese Medicine between January 2016 and October 2020. Among them, 360 patients receiving sodium nitroprusside immediately before balloon inflation during PCI were enrolled in an experimental group between January 2019 and October 2020 and 380 patients receiving sodium nitroprusside after incident no reflow and slow flow during PCI were enrolled in a control group between January 2016 and January 2019. The occurrence of no reflow and slow flow was compared between the two groups and left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) were detected 1 mo after the operation.

RESULTS

After treatment, the proportion of patients with thrombolysis in myocardial infarction flow grades 0 to II was lower in the experimental group than in the control group (*P* < 0.05). At 1 mo after treatment, LVEDD was lower and LVEF was higher in the experimental group than in the control group (*P* < 0.05). In terms of incidence of adverse cardiovascular events within 1 mo after treatment, in the experimental group, malignant arrhythmia occurred in three patients, intractable myocardial ischemia in three, congestive heart failure in four, and recurrent myocardial infarction in five; one patient died. In the control group, malignant arrhythmia occurred in eight patients, intractable myocardial ischemia in five, congestive heart failure in seven, and recurrent myocardial infarction in 14; two patients died. The incidence of adverse cardiovascular events was 4.4% in experimental group which was lower than that of the control group at 1 mo after operation (9.5%; *P* < 0.05).

CONCLUSION

Administration of sodium nitroprusside into target vessels immediately before balloon inflation can significantly reduce the incidence of no reflow and slow flow, improve LVEDD and LVEF, and reduce the incidence of adverse cardiovascular events in patients treated by PCI. It is worthy of clinical promotion.

**Key Words:** Sodium nitroprusside; No reflow; Slow blood flow; Coronary artery disease; Percutaneous coronary intervention

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Yu Y, Yang BP. Sodium nitroprusside injection immediately before balloon inflation during percutaneous coronary intervention. *World J Clin Cases* 2021; 9(36): 11248-11254

**URL:** https://www.wjgnet.com/2307-8960/full/v9/i36/11248.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v9.i36.11248

**Core Tip:** Thepresent study explored the effectiveness of coronary injection with nitroprusside, a commonly used vasodilator, as a pharmacological intervention strategy administered before balloon inflation for the prevention of no reflow or slow flow during percutaneous coronary intervention. The results showed that preventive use of sodium nitroprusside proved beneficial. It resulted in improved coronary blood flow and outcome of percutaneous coronary intervention.

**INTRODUCTION**

Coronary heart disease (CHD) is a common cardiac disease and percutaneous coronary intervention (PCI) is an effective therapy for CHD with a high success rate[1-3]. Postoperative remission determines outcomes and quality of life in patients with CHD. However, no obvious stenosis was reported in the affected vessels in 5% to 30% patients after revascularization in stenosis or occlusion of the coronary artery. However, angiographic results indicated that antegrade flow was decreased or lost. Coronary angiographic results indicated that thrombolysis in myocardial infarction (TIMI) flow grades 0 to II are classified as coronary slow flow or no re-flow[4-6]. Coronary slow flow or no re-flow may lead to microcirculation hypoperfusion, continuous myocardial ischemia, abnormal myocardial metabolism in cancer cells, poor prognosis, rise in mortality, reinfarction rate, reinfarction rate, and reoperation rate, cardiac insufficiency, ventricular dilatation, obvious reconstruction, and increased mortality[7]. Sodium nitroprusside is usually used for vascular relaxation in the coronary microcirculation of patients with CHD. Sodium nitroprusside releases NO into blood, which is then degraded into bradykinin and dilate microvascular vessels and improve myocardial perfusion[8]. Previous studies[9,10] showed that sodium nitroprusside can improve blood flow in patients with no reflow and slow flow undergoing reperfusion. The present study aimed to explore whether target intravascular sodium nitroprusside injection immediately before balloon inflation or preventive use of sodium nitroprusside can reduce the incidence of no reflow and slow flow during PCI.

**MATERIALS AND METHODS**

***Research data***

A retrospective study was conducted in 740 patients undergoing PCI at Gansu Provincial Hospital of Traditional Chinese Medicine between January 2016 and October 2020. Three hundred and sixty patients who were admitted to the hospital from January 2019 to October 2020 were included in an experimental group and 380 patients who were admitted to the hospital from January 2016 to January 2019 were included in a control group. Eligible participants included patients who ranged in age from 18 to 70 years, were diagnosed with CHD, or had a history of CHD with > 70% stenosis of the coronary artery on coronarography. Patients complicated with severe heart, lung, liver, and kidney dysfunction, severe diseases which caused psychological disorders or poor compliance, or other malignant cancer, and patients in poor physical condition and who are unable to tolerate surgery were excluded from the study. In the experimental group, 248 patients were male and 112 were female with average age of 32 to 68 (61.23 ± 10.14) years. Of them, 203 patients had a history of smoking and 157 were non-smokers. In terms of comorbidities, 187 patients had hypertension, 183 had hyperlipidemia, and 115 had a history of diabetes. For thrombolysis in myocardial infarction (TIMI) flow grade, 338 patients had TIMI grades 0 to II and 22 had TIMI grade III. Infarction occurred in the anterior descending branch in 119 patients, in the circumflex branch in 123, and in the right coronary artery in 127. The average lesion length was 23.09 ± 5.67 mm. Balloon inflation was performed 1.87 ± 0.62 times. The proportion of stenosis was 83.69 ± 7.21%. In the control group, 261 patients were male and 119 were female. The average age was 31 to 69 (62.35 ± 11.47) years. Of them, 212 were smokers and 168 were non-smokers, 196 patients had hypertension, 188 had hyperlipidemia, and 121 had diabetes. With regards to TIMI flow grade, 345 patients had TIMI grades 0 to II and 35 had TIMI grade III. Infarction occurred in the anterior descending branch in 131 patients, in the circumflex branch in 128, and in the right coronary artery in 134. The average lesion length was 22.96 ± 6.12 mm. Balloon inflation was performed 1.87 ± 0.62 times. The proportion of stenosis was 82.37 ± 7.19%. There was no significant difference in general information such as age, gender, or disease type between the two groups with high compatibility (*P* > 0.05).

***Research methods***

All patients received oral aspirin (Bayer Healthcare Co Ltd, Cat. No. J20130078) 300 mg and tegrello (AstraZeneca AB, Cat. No. J20130020) 180 mg before undergoing acute PCI in the catheter room. Arterial puncture was achieved through the radial artery or the femoral artery. Then, low molecular weight heparin calcium injection (Sanofi Winthrop Industrie, Cat. No. H20080481) 3000 IU was administered. The experimental group received target intravascular sodium nitroprusside injection 200 μg immediately before balloon inflation (China Resources Double-Crane Pharmaceutical Co. Ltd., Cat. No. H11020635). The control group received sodium nitroprusside injection after no reflow and slow flow occurred during the operation.

***Measures***

The outcomes of the study included the incidence of no reflow and slow flow during PCI which was assessed by two experienced interventional physicians 30 min after the treatment. The diagnostic criteria were TIMI grade for antegrade flow < II after PCI when no obvious stenosis was reported in the affected vessels[11]. Left cardiac function indexes were compared, including left ventricular end-diastolic dimension (LVEDD) and left ventricular ejection fraction (LVEF) at 1 mo after the operation. The incidence of adverse cardiac events was compared, including malignant arrhythmia, intractable myocardial ischemia, congestive heart failure, recurrent myocardial infarctions, and death at 1 mo after the operation.

***Statistical analysis***

SPSS22.0 software was used for data processing. Quantitative data are expressed as the mean ± SD. Qualitative data are expressed as percentages. Inter-group difference was compared using c2 test. *P* < 0.05 represented that there was a significant difference.

**RESULTS**

For posttreatment TIMI flow grade, the proportion of patients who had TIMI grades 0 to II was lower in the experimental group than in the control group, and the proportion of patients who had TIMI grade III was higher in the experimental group than in the control group (*P* < 0.05; Table 1).

When comparing left ventricular function indices between the two groups, it was found that LVEDD was lower and LVEF was higher in the experimental group than in the control group (*P* < 0.05; Table 2).

In terms of incidence of adverse cardiovascular events within 1 mo after treatment, in the experimental group, malignant arrhythmia occurred in three patients, intractable myocardial ischemia in three, congestive heart failure in four, and recurrent myocardial infarction in five; one patient died. In the control group, malignant arrhythmia occurred in eight patients, intractable myocardial ischemia in five, congestive heart failure in seven, and recurrent myocardial infarction in 14; two patients died. The incidence of adverse cardiovascular events was 4.4% in the experimental group, which was lower than that of the control group at 1 mo after operation (9.5%; *P* < 0.05; Table 3).

**DISCUSSION**

PCI is one of the most used choices for the treatment of coronary heart disease. It opens blocked arteries, improves function of the heart, and protects cardiac muscle cells in a short time[12,13]. Sodium nitroprusside helps alleviate no reflow and slow flow during PCI, reduce myocardial microdamage, modulate local inflammatory response to protect cardiac muscle cells, improve heart function, cardiac ejection function, and outcomes, and reduce adverse cardiac events[14,15]. The present study explored whether preventive use of sodium nitroprusside or intravascular sodium nitroprusside injection immediately before balloon inflation can reduce no reflow and slow flow during PCI.

Coexisting diseases such as diabetes, hypertension, hyperlipemia, and multiple microangiopathic lesions are common in patients with coronary heart disease, leading to a high risk of no reflow and slow flow associated with PCI[16]. The occurrence of no reflow and slow flow may be attributed to distal microembolization of the coronary circulation, injury associated with microvascular reperfusion microvascular obstruction, and spasm[17,18]. Moreover, blood platelet and leukocyte levels, cell swelling in the myocardium, and stromal edema may cause no reflow and slow flow. Sodium nitroprusside as a vasodilator is used in patients experiencing no reflow and slow flow during PCI[19]. Sodium nitroprusside functions as an NO direct donor, releasing NO into the vascular vessels, which may result in significant dilation of arterioles and improvement of coronary microcirculation[20]. The present study found that target intravascular sodium nitroprusside injection immediately before balloon inflation can significantly reduce the incidence of no reflow and slow flow during PCI. This can be explained by timely use of sodium nitroprusside which can prevent reperfusion injury[21]. Meanwhile, target intravascular sodium nitroprusside injection immediately before balloon inflation over 1 mo can reduce LVEDD and increase LVEF, suggesting that sodium nitroprusside injection immediately before balloon inflation can improve outcomes and cardiac ejection function. This may be attributed to reduced time of reperfusion. Thus, it can effectively open vessels, relieve a blockage, and reduce reperfusion injury[22-24]. Furthermore, the current study revealed that target intravascular sodium nitroprusside injection immediately before balloon inflation can reduce the incidence of adverse cardiac events at 1 mo and improve long-term treatment effectiveness.

**CONCLUSION**

In summary, target intravascular sodium nitroprusside injection immediately before balloon inflation can reduce the incidence of no reflow and slow flow during PCI, significantly improving LVEDD and LVEF and reducing postoperative incidence of adverse cardiac events. Multi-center large sample studies are needed to further verify the findings of the study.

**ARTICLE HIGHLIGHTS**

***Research background***

The incidence of no reflow or slow flow appears to be high in patients with coronary heart disease (CHD) undergoing percutaneous coronary intervention (PCI). This may lead to microvascular obstruction and endothelial disruption. Nipride has been proved effective in treating no reflow or slow flow.

***Research motivation***

How does sodium nitroprusside benefit in the prevention of no reflow or slow flow? Does the time of administration affect the efficacy of sodium nitroprusside in the prevention of no reflow or slow flow?

***Research objectives***

The present study was conducted to evaluate efficacy and usefulness of sodium nitroprusside administrated before balloon inflation in prevention of no reflow or slow flow.

***Research methods***

Patients with CHD undergoing PCI were included. They were divided into two groups. The experimental group received sodium nitroprusside immediately before balloon inflation and the control group received sodium nitroprusside after no reflow or slow flow occurred during the PCI. The incidence of no reflow or slow flow was compared between the two groups. Moreover, thrombolysis in myocardial infarction (TIMI) grade, cardiac function, and adverse events were also compared between the two groups.

***Research results***

TIMI grade and cardiac function were better in the experimental group than in the control group. The incidence of adverse events was lower in the experimental group than in the control group.

***Research conclusions***

Sodium nitroprusside administrated immediately before balloon inflation is useful for the prevention of no reflow or slow flow during PCI.

***Research perspectives***

Long-term, larger sample size and high-quality follow-up RCTs are needed for preventive use of sodium nitroprusside in patients with cardiac disease undergoing PCI.

**REFERENCES**

1 **Mahmoud MS,** Hanan KK, Mohammad EE. Assessment of the Clinical and Procedural Predictive Factors of No-Reflow Phenomenon Following Primary Percutaneous Coronary Intervention. *Med J Cairo Univ* 2021; **89**: 409-417

2 **Esenboğa K**, Kurtul A, Yamantürk YY, Tan TS, Tutar DE. Systemic immune-inflammation index predicts no-reflow phenomenon after primary percutaneous coronary intervention. *Acta Cardiol* 2021: 1-8 [PMID: 33612077 DOI: 10.1080/00015385.2021.1884786]

3 **Rezkalla SH**, Stankowski RV, Hanna J, Kloner RA. Management of No-Reflow Phenomenon in the Catheterization Laboratory. *JACC Cardiovasc Interv* 2017; **10**: 215-223 [PMID: 28183461 DOI: 10.1016/j.jcin.2016.11.059]

4 **Zhao S**, Qi G, Tian W, Chen L, Sun Y. Effect of intracoronary nitroprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention: a meta-analysis. *J Interv Cardiol* 2014; **27**: 356-364 [PMID: 25041036 DOI: 10.1111/joic.12133]

5 **Niu X**, Zhang J, Bai M, Peng Y, Sun S, Zhang Z. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis. *BMC Cardiovasc Disord* 2018; **18**: 3 [PMID: 29320987 DOI: 10.1186/s12872-017-0722-z]

6 **Su Q**, Li L, Naing KA, Sun Y. Safety and effectiveness of nitroprusside in preventing no-reflow during percutaneous coronary intervention: a systematic review. *Cell Biochem Biophys* 2014; **68**: 201-206 [PMID: 23749494 DOI: 10.1007/s12013-013-9690-9]

7 **Qi Q**, Niu J, Chen T, Yin H, Wang T, Jiang Z. Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction. *Med Sci Monit* 2018; **24**: 2767-2776 [PMID: 29726480 DOI: 10.12659/MSM.906815]

8 **Zhang W**, Dai J, Zheng X, Xu K, Yang X, Shen L, Wang X, Hao Z, Qiu X, Jiang L, Shi H, Shen L, He B. Myocardial protective effect of intracoronary administration of nicorandil and alprostadil *via* targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial. *Medicine (Baltimore)* 2021; **100**: e25551 [PMID: 33847683 DOI: 10.1097/MD.0000000000025551]

9 **Lyu J**, Zheng XT, Li YP. Sodium nitroprusside and dopamine for the treatment of severe congestive heart failure: A clinical observation. *Xinxueguan Kangfu Yixue Zazhi* 2009; **18**: 284-286

10 **Hao YX**. Effect of balloon dilatation after stent placement on long-term outcomes in patients with ST-elevation myocardial infarction undergoing acute percutaneous coronary intervention. M.Sc. Thesis, Capital Medical University. 2015. Available from: https://d.wanfangdata.com.cn/thesis/Y3144738

11 **An S**, Huang H, Wang H, Jiang Y. Prophylactically injection of Nicorandil to reduce no-reflow phenomenon during PCI in acute STEMI patients: Protocol of a double-blinded, randomized, placebo-controlled trial. *Medicine (Baltimore)* 2021; **100**: e25500 [PMID: 33847663 DOI: 10.1097/MD.0000000000025500]

12 **Zhou SS**, Tian F, Chen YD, Wang J, Sun ZJ, Guo J, Jin QH. Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction. *J Geriatr Cardiol* 2015; **12**: 135-142 [PMID: 25870616 DOI: 10.11909/j.issn.1671-5411.2015.02.003]

13 **Celik T**, Balta S, Ozturk C, Kaya MG, Aparci M, Yildirim OA, Demir M, Unlu M, Demirkol S, Kilic S, Iyisoy A. Predictors of No-Reflow Phenomenon in Young Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Angiology* 2016; **67**: 683-689 [PMID: 26369341 DOI: 10.1177/0003319715605977]

14 **Zhao YJ**, Fu XH, Ma XX, Wang DY, Dong QL, Wang YB, Li W, Xing K, Gu XS, Jiang YF. Intracoronary fixed dose of nitroprusside *via* thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction. *Exp Ther Med* 2013; **6**: 479-484 [PMID: 24137212 DOI: 10.3892/etm.2013.1139]

15 **Yang L**, Mu L, Sun L, Qi F, Guo R. Effect of intracoronary nitroprusside injection on flow recovery during primary PCI in acute STEMI patients. *Minerva Cardioangiol* 2017; **65**: 111-118 [PMID: 27249789 DOI: 10.23736/S0026-4725.16.04126-8]

16 **Kobatake R**, Sato T, Fujiwara Y, Sunami H, Yoshioka R, Ikeda T, Saito H, Ujihira T. Comparison of the effects of nitroprusside versusnicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. *Heart Vessels* 2011; **26**: 379-384 [PMID: 21110199 DOI: 10.1007/s00380-010-0065-5]

17 **Shinozaki N**, Ichinose H, Yahikozawa K, Shimada H, Hoshino K. Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction. *Int Heart J* 2007; **48**: 423-433 [PMID: 17827814 DOI: 10.1536/ihj.48.423]

18 **Chen GX**, Wang HN, Zou JL, Yuan XX. Effects of intracoronary injection of nicorandil and tirofiban on myocardial perfusion and short-term prognosis in elderly patients with acute ST-segment elevation myocardial infarction after emergency PCI. *World J Emerg Med* 2020; **11**: 157-163 [PMID: 32351648 DOI: 10.5847/wjem.j.1920-8642.2020.03.005]

19 **Li M**, Wu Z, Yuan Y, Feng L, Lao Y, Guo Z. Delayed angioplasty is superior to an emergency strategy in ST-segment elevation myocardial infarction patients who present late and with infarct artery spontaneous reperfusion before intervention. *Cardiovasc J Afr* 2019; **30**: 162-167 [PMID: 31144708 DOI: 10.5830/CVJA-2019-009]

20 **Nishio M**, Ueda Y, Matsuo K, Tsujimoto M, Hao H, Asai M, Nemoto T, Wada M, Hirata A, Murakami A, Kashiwase K, Kodama K. Association of target lesion characteristics evaluated by coronary computed tomography angiography and plaque debris distal embolization during percutaneous coronary intervention. *Circ J* 2014; **78**: 2203-2208 [PMID: 24998191 DOI: 10.1253/circj.cj-14-0103]

21 **Garcia JR**, Campbell PF, Kumar G, Langberg JJ, Cesar L, Wang L, García AJ, Levit RD. A Minimally Invasive, Translational Method to Deliver Hydrogels to the Heart Through the Pericardial Space. *JACC Basic Transl Sci* 2017; **2**: 601-609 [PMID: 30062173 DOI: 10.1016/j.jacbts.2017.06.003]

22 **Gu J**, Zhuo Y, Liu TJ, Li J, Yin ZF, Xu ZJ, Fan L, He Q, Chen K, Zeng HS, Wang XF, Fan YQ, Zhang JF, Liang FY, Wang CQ. Balloon Deflation Strategy during Primary Percutaneous Coronary Intervention in Acute ST-Segment Elevation Myocardial Infarction: A Randomized Controlled Clinical Trial and Numerical Simulation-Based Analysis. *Cardiol Res Pract* 2020; **2020**: 4826073 [PMID: 32963824 DOI: 10.1155/2020/4826073]

23 **Feng C**, Han B, Liu Y, Wang L, Niu D, Lou M, Lu C. Effect of nicorandil administration on myocardial microcirculation during primary percutaneous coronary intervention in patients with acute myocardial infarction. *Postepy Kardiol Interwencyjnej* 2018; **14**: 26-31 [PMID: 29743901 DOI: 10.5114/aic.2018.74352]

24 **Gao MD**, Zhang EY, Liu YY, Li XW, Xiao JY, Sun GY, Liu Y. Intracoronary pressure gradient measurement in acute myocardial infarction patients with the no-reflow phenomenon during primary percutaneous coronary intervention. *Chin Med J (Engl)* 2020; **133**: 766-772 [PMID: 32149760 DOI: 10.1097/CM9.0000000000000709]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Gansu Provincial Hospital of Traditional Chinese Medicine Institutional Review Board.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** None.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 10, 2021

**First decision:** September 2, 2021

**Article in press:** November 3, 2021

**Specialty type:** Cardiac and Cardiovascular Systems

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Sip M **S-Editor:** Wang JL **L-Editor:** Wang TQ **P-Editor:**

**Table 1 Posttreatment thrombolysis in myocardial infarction flow grade of diseased vessels, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | ***n*** | **TIMI** | |
| **Grades 0 to II** | **Grade III** |
| Experimental | 360 | 28 (7.8) | 332 (92.2) |
| Control | 380 | 79 (20.8) | 301 (79.2) |
| *χ*2 value |  | 12.422 | 12.422 |
| *P* value |  | 0.001 | 0.001 |

TIMI: Thrombolysis in myocardial infarction.

**Table 2 Comparison of left ventricular function indices between the two groups**

|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | ***n*** | **LVEDD (mm)** | **LVEF (%)** |
| Experimental | 360 | 54.21 ± 5.38 | 50.83 ± 8.38 |
| Control | 380 | 56.78 ± 4.90 | 47.56 ± 5.47 |
| *t* value |  | 6.329 | 7.542 |
| *P* value |  | 0.034 | 0.027 |

LVEDD: Left ventricular end-diastolic diameter; LVEF: Left ventricular ejection fraction.

**Table 3 Comparison of adverse cardiovascular events between the two groups at 1 mo after operation, *n* (%)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Group** | ***n*** | **Malignant arrhythmia** | **Intractable myocardial ischemia** | **Congestive heart failure** | **Recurrent myocardial infarction** | **Death** | **Overall incidence** |
| Experimental | 360 | 3 | 3 | 4 | 5 | 1 | 16 (4.4) |
| Control | 380 | 8 | 5 | 7 | 14 | 2 | 36 (9.5) |
| *χ*2 value |  |  |  |  |  |  | 9.124 |
| *P* value |  |  |  |  |  |  | 0.001 |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**